| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CytoDyn Inc (OTCQB: CYDY)
CYDY Technical Analysis
1
| As on 23rd Oct 2024 CYDY STOCK Price closed @ 0.13 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CYDYSTOCK Price
| Open | 0.14 | Change | Price | % |
| High | 0.15 | 1 Day | N/A | N/A |
| Low | 0.13 | 1 Week | 0.00 | 0.00 |
| Close | 0.13 | 1 Month | 0.00 | 0.00 |
| Volume | 3245920 | 1 Year | 0.00 | 0.00 |
| 52 Week High 0.00 | 52 Week Low 0.00 | ||||
OTCQB USA Most Active Stocks
| EFSH | 0.48 | % |
| AREB | 3.07 | % |
| BMIX | 0.01 | % |
| SYAXF | 0.02 | % |
| CYDY | 0.13 | % |
| FMCC | 1.32 | % |
| ALPP | 3.56 | 0.00% |
| ALPP | 3.56 | 0.00% |
| FNMA | 1.44 | % |
| FNMAS | 5.46 | % |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| CYDY Daily Charts |
CYDY Intraday Charts |
Whats New @ Bazaartrend |
CYDY Free Analysis |
|
|
CYDY Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
CYDY Forecast October 2024
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
CYDY Weekly Forecast
| 4th UP Forecast | 0.00 |
| 3rd UP Forecast | 0.00 |
| 2nd UP Forecast | 0.00 |
| 1st UP Forecast | 0.00 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | 0.00 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | 0.00 |
CYDY Forecast2024
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
CytoDyn Inc ( OTCQB USA Symbol : CYDY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CYDY Business Profile
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Address: 1111 Main Street, Vancouver, WA, United States, 98660
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service